FDA Final Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” http://www.fda.gov/cber/guidelines.htm#cjdvcjd

2/19/02


Click here to start


Table of Contents

FDA Final Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” http://www.fda.gov/cber/guidelines.htm#cjdvcjd

Geographic Donor Deferrals for vCJD Risk

FDA Draft Guidance: Donor Deferrals Phase I Implementation 5/31/02

FDA Draft Guidance: Donor Deferrals Phase II Implementation 10/31/02

Source Plasma

Source Plasma

Final Guidance: Changes

Continuing Issues: Non-European BSE

Continued Issues

Removal of vCJD agent and TSE’s by Plasma Fractionation

Author: scottd